ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- ASIT biotech reintroduces an application for judicial reorganization and modifies the composition of its board of directors Monday, 20 January 2020
- ASIT Biotech_next steps Friday, 20 December 2019
- ASIT biotech gp-ASIT+TM Phase III trial in grass pollen allergy did not meet the primary endpoint Monday, 25 November 2019 All ASIT news